<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82398">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02034448</url>
  </required_header>
  <id_info>
    <org_study_id>CRRTNet</org_study_id>
    <nct_id>NCT02034448</nct_id>
  </id_info>
  <brief_title>CRRTNet Registry- A Prospective Observational Registry</brief_title>
  <acronym>CRRT</acronym>
  <official_title>CRRTNet Outcome Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AKI Critical Care Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AKI Critical Care Research Foundation</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An observational registry to monitor the outcome of CRRT in adults with acute kidney injury.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Continuous Renal Replacement Therapy (CRRT) is a form of dialysis provided to critically ill
      patients with acute renal failure, now known as acute kidney injury (AKI).  While we have
      extensive experience with this therapy in critically ill patients, there is no consensus on
      when to start CRRT or a clinical standard as to the best possible way to deliver the
      therapy.  Previous studies have examined one aspect of CRRT in detail (for instance the dose
      of delivered therapy, or anticoagulation strategies) or have been small single center
      studies, or large multinational studies examining very basic practice patterns.  This is a
      prospective observational cohort study.  All patients who receive CRRT as part of their
      standard of local care will be eligible for the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of Stay</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Continuous Renal Replacement Therapy</condition>
  <arm_group>
    <arm_group_label>Acute Kidney Injury</arm_group_label>
    <description>CRRT intervention with adult patients with Acute Kidney Injury</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Continuous Renal Replacement Therapy</intervention_name>
    <arm_group_label>Acute Kidney Injury</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This is a prospective observational registry.  A minimum sample size of 2000 patients with
        the detailed information being obtained would embody the largest and most detailed
        repository of adult CRRT patient information available.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: Patients initiating CRRT c. Age &gt; 18 years of age and &lt;89 year of age
        -

        Exclusion Criteria: Ë‚ 18 years of age and &gt; 89 year of age

        -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mike Heung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mike Heung</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mike Heung, MD</last_name>
      <phone>734-936-4890</phone>
      <email>mheung@umich.edu</email>
    </contact>
    <investigator>
      <last_name>Mike Heung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 10, 2014</lastchanged_date>
  <firstreceived_date>January 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CRRT</keyword>
  <keyword>Renal</keyword>
  <keyword>Kidney</keyword>
  <keyword>adults</keyword>
  <keyword>registry</keyword>
  <keyword>AKI</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
